appScorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
News & Opinions
Biocon share price gains as USFDA issues ‘no observations’ on Bengaluru facility
12 hours ago•Moneycontrol
News Video
Important Stocks Now | Competitor की हरकत से डूब रहा Biocon ? Zomato में क्या पाक रहा है? | Business
3 days ago•CNBC Awaaz.
News Video
इस Company ने Biocon के Blockbuster Drug को 85% के Discount के साथ किया लॉन्च, अब नह बचेगा ये Stock?
3 days ago•CNBC Awaaz.
Biocon Biologics may raise additional equity of $300 million in FY24 to pare debt
1 week ago•Economic Times
Biocon IPO after integration of Viatris market: MD & CEO Shreehas Tambe
1 week ago•Business Standard
Biocon shares trim most of early gains, end flat amid profit-taking
1 week ago•Business Standard
Biocon shares jump 8% post Q4 results. Is the Street happy?
1 week ago•Economic Times
Trying to raise an additional $300 million to further reduce debt: Kiran Mazumdar Shaw, Biocon
1 week ago•Economic Times
Biocon Q4FY23 profit up 31.3% at Rs 313.20 crore on robust sales, beats estimates | The Financial Express
1 week ago•Financial Express
News Video
Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report
1 week ago•CNBC-TV18